VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ONCY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ONCYOncolytics Biotech Inc.
$0.44$56M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ONCY
  4. Financial Ratios

Oncolytics Biotech Inc. (ONCY) Financial Ratios

Latest Ratios: P/E Ratio -2.1x · EV/EBITDA N/A · ROE -7467.2%. (1999–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ONCY Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$56M$84M$70M$91M$95M$74M$96M$105M$29M$76M$25M
Enterprise Value$52M$77M$55M$57M$83M$34M$65M$92M$15M$64M$13M
P/E Ratio →-2.15——————————
P/S Ratio———————————
P/B Ratio——11.683.313.572.063.88—4.689.122.36
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

ONCY EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue———————————
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

ONCY Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin———————————
Operating Margin———————————
Net Profit Margin———————————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-7467.2%-7467.2%-135.9%-77.4%-58.5%-86.5%-182.6%-1496.6%-235.3%-164.6%-85.6%
ROA-188.0%-188.0%-77.3%-54.9%-44.0%-65.6%-83.3%-263.9%-103.2%-94.9%-71.9%
ROIC———-461.3%-278.1%——————
ROCE-369.9%-369.9%-106.2%-74.9%-51.8%-70.1%-132.5%-213.8%-133.5%-132.2%-86.5%

ONCY Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity——0.180.020.010.020.02————
Debt / EBITDA———————————
Net Debt / Equity——-2.49-1.25-0.43-1.12-1.25—-2.21-1.43-1.13
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage———————————

Net cash position: cash ($7M) exceeds total debt ($772509)

ONCY Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.121.122.829.019.0516.6912.451.475.133.413.55
Quick Ratio1.121.122.829.019.0516.6912.451.475.133.413.55
Cash Ratio0.850.852.388.248.1515.3411.521.104.872.263.47
Asset Turnover———————————
Inventory Turnover———————————
Days Sales Outstanding———————————

ONCY Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$96M$76M$68M$58M$54M$40M$22M$16M$14M$13M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity depletion risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Liquidity Buffer Nearing Critical Exhaustion

According to recent quarterly filings, the company's current ratio has compressed significantly from 9.01 in 2023Q4 to 1.38 in 2026Q1, signaling a rapid depletion of the liquid assets necessary to sustain ongoing clinical trial operations without immediate external capital injections or partnership-driven milestone payments.

The sharp decline in the current ratio suggests that the company's ability to cover short-term obligations is becoming increasingly precarious. Investors should monitor the narrowing gap between cash reserves and accrued liabilities, as the current liquidity profile leaves little room for operational delays or unexpected clinical trial cost overruns.

Debt-to-Equity Imbalance Signals Financial Strain

Based on reported financial statements, the company's debt-to-equity ratio has experienced extreme volatility, peaking at 7.26 in 2025Q3, which reflects the compounding impact of persistent net losses and the erosion of shareholder equity as the firm continues to fund its development-stage pipeline through dilutive financing.

The shift toward negative equity suggests that the company's capital structure is under significant pressure, rendering traditional leverage metrics less meaningful. This trend warrants further investigation into the long-term sustainability of the current financing model, particularly as the firm lacks the operating cash flow to service debt obligations.

Capital Efficiency Decaying Amidst Losses

As reported in historical financial data, the company's return on assets has consistently remained in negative territory, reaching -163.8% in 2026Q1, which underscores the fundamental challenge of generating returns on invested capital while the firm remains in a pre-revenue, high-burn clinical development phase.

The persistent negative ROA indicates that capital is being consumed at a rate that far outpaces the progress of clinical milestones. This trend suggests that the company is currently destroying shareholder value rather than compounding it, a reality that will likely persist until the firm can demonstrate a clear path to commercialization.

Misapplication of Traditional Valuation Multiples

Based on an analysis of the company's financial profile, the price-to-earnings ratio is the most commonly misapplied metric, as it obscures the reality that the firm is a pre-revenue entity where earnings are non-existent and losses are driven by necessary, yet non-recurring, clinical development expenditures.

Investors should instead focus on cash-to-milestone ratios or the clinical trial burn rate, as these metrics provide a more accurate assessment of the company's operational runway. Relying on P/E multiples in this context is misleading and fails to capture the binary nature of the firm's underlying biotechnology assets.

Download Financial Ratios Data

Includes 30+ ratios · 27 years · Updated daily

Consensus & Technical Research Suite
Open ONCY Terminal

ONCY Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ONCY — Frequently Asked Questions

Quick answers to the most common questions about buying ONCY stock.

What is Oncolytics Biotech Inc.'s P/E ratio?

Oncolytics Biotech Inc.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.

What is Oncolytics Biotech Inc.'s ROE?

Oncolytics Biotech Inc.'s return on equity (ROE) is -7467.2%. The historical average is -84.5%.

Is ONCY stock overvalued?

Based on historical data, Oncolytics Biotech Inc. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.